Guided Therapeutics Posts $0 Revenue, $1.01M Q1 Loss; Advances FDA PMA Filing for Key Device
GTHP has more than doubled off its 52-week low of $0.064.
Summary
Guided Therapeutics Inc. reported Q1 2026 financial results with no revenue and a net loss of $1.01 million, or $0.01 per share, an increase in loss from the prior year. For a company with a market capitalization of approximately $19 million, this burn rate is significant. However, the company also provided critical operational updates, including the completion of a pivotal U.S. trial and plans to file an FDA PMA in Q2 2026, alongside an ongoing China NMPA review. These regulatory milestones are crucial for a pre-revenue medical device company. Management anticipates approximately $1.0 million in potential sales over the next 12 months, with $200,000 in confirmed orders for Turkey and Indonesia. Traders will be watching for the FDA PMA filing, the outcome of the China NMPA review, and progress on commercialization efforts to generate revenue.
At the time of this announcement, GTHP was trading at $0.20 on OTC in the Life Sciences sector, with a market capitalization of approximately $19.3M. The 52-week trading range was $0.06 to $0.54. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.